-
Does tight control of disease impede radiological progression? The radiographic outcomes of the TICOPA study. J. Rheumatol. (IF 3.6) Pub Date : 2025-02-01 Lija James,Philip S Helliwell,Elizabeth Hensor,Philip G Conaghan,Paul Emery,Laura C Coates
OBJECTIVE The Tight Control of Psoriatic Arthritis (TICOPA) study was the first to undertake treat-to-target approach in PsA. Our aim was to further investigate the radiographic changes in the TICOPA study. METHODS The TICOPA trial recruited patients with early DMARD naïve psoriatic arthritis (PsA). Plain radiographs of the hands and feet were taken at weeks 0 and 48. Clinical outcomes were recorded
-
Impact of age on active and structural MRI lesions in sacroiliac joints of healthy individuals and non-specific back pain patients. J. Rheumatol. (IF 3.6) Pub Date : 2025-02-01 Ulrich Weber,Sengül Seven,Susanne J Pedersen,Mikkel Østergaard,Pedro M Machado,Stephanie Wichuk,Xenofon Baraliakos,Robert G W Lambert,Walter P Maksymowych
OBJECTIVE To assess the impact of increasing age on the frequency of inflammatory and structural MRI lesions in the sacroiliac joints (SIJ) in 3 independent cohorts of healthy individuals and non-specific back pain (NSBP) patients. METHODS We assessed MRI SIJ lesions in 3 cohorts A/B/C of healthy individuals (cohorts A/B: n=79/78) and NSBP patients (cohorts A/C: n=87/46) aged ≤45 years referred with
-
Not Everything is Osteoporosis: Multiple Low-Impact Fractures in an Adult Female Patient. J. Rheumatol. (IF 3.6) Pub Date : 2025-02-01 Caroline Mazeda,Sofia Azevedo,Sérgio Sousa,Anabela Barcelos
-
Bimekizumab Improves Patient-Reported Outcomes and Work Productivity in Patients with Psoriatic Arthritis: 1-Year Results from Two Phase 3 Studies. J. Rheumatol. (IF 3.6) Pub Date : 2025-02-01 Dafna D Gladman,Philip J Mease,Laure Gossec,M Elaine Husni,Alice B Gottlieb,Barbara Ink,Rajan Bajracharya,Jason Coarse,Nikos Lyris,Jérémy Lambert,William Tillett
OBJECTIVE To assess the longer-term impact of bimekizumab to 1 year on patient-reported symptoms, health-related quality of life (HRQoL), and work productivity in patients with active PsA who were biologic disease-modifying antirheumatic drug (bDMARD)-naïve or had inadequate response/intolerance to tumor necrosis factor inhibitors (TNFi-IR) up to 1 year. METHODS BE OPTIMAL (NCT03895203; bDMARD-naïve)
-
TREX1-Associated Familial Chilblain Lupus With Cerebral Aneurysms Treated With Janus Kinase Inhibition. J. Rheumatol. (IF 3.6) Pub Date : 2025-02-01 Lindsay K Cho,Volodko Bakowsky,Alexandra Legge
-
The Boutonniere Deformity and Piano Key Sign Depicted in a 12th-Century Chinese Painting. J. Rheumatol. (IF 3.6) Pub Date : 2025-02-01 Qiman Liu,Haojie Xu
-
Unacceptable work state in rheumatoid arthritis: establishment of thresholds for presenteeism and clinical measurement instruments. J. Rheumatol. (IF 3.6) Pub Date : 2025-02-01 Dafne Capelusnik,Sofia Ramiro,Elena Nikiphorou,Walter P Maksymowych,Marina Nighat Magrey,Helena Marzo-Ortega,Annelies Boonen
OBJECTIVE To 1) identify threshold values of presenteeism measurement instruments that reflect unacceptable work state in employed RA patients and whether those thresholds can predict future adverse work outcomes (AWO); 2) to assess among patients with RA the performance of presenteeism thresholds previously established in axSpA for the same instruments. METHODS Data from the multinational RA-PROSE
-
Predictors of secukinumab treatment response and continuation in axial spondyloarthritis: results from the EuroSpA research collaboration network. J. Rheumatol. (IF 3.6) Pub Date : 2025-02-01 Marion Pons,Stylianos Georgiadis,Merete Lund Hetland,Zohra Faizy Ahmadzay,Simon Rasmussen,Sara Nysom Christensen,Daniela Di Giuseppe,Johan K Wallman,Karel Pavelka,Jakub Závada,Catalin Codreanu,Bente Glintborg,Anne Gitte Loft,Helena Santos,Maria Helena Lourenço,Michael J Nissen,Adrian Ciurea,Laura Kuusalo,Vappu Rantalaiho,Brigitte Michelsen,Pawel Mielnik,Katja Perdan Pirkmajer,Ziga Rotar,Bjorn Gudbjornsson
OBJECTIVE In patients with axial spondyloarthritis (axSpA) initiating secukinumab, we aimed to identify baseline (treatment start) predictors of achieving low disease activity (LDA) after 6 months, as measured by Axial Spondyloarthritis Disease Activity Score using C-reactive protein (ASDAS-CRP) and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), as well as treatment continuation after
-
Novel Photon-Counting Computed Tomography for the Evaluation of Large-Vessel Giant Cell Arteritis. J. Rheumatol. (IF 3.6) Pub Date : 2025-02-01 Sehreen Mumtaz,Matthew J Koster,Kenneth J Warrington
-
Historical Perspective on Antinuclear Antibody Testing. J. Rheumatol. (IF 3.6) Pub Date : 2025-02-01 Gyorgy Abel,M Qasim Ansari,Melissa R Snyder,Anne E Tebo,Mark H Wener,Stanley J Naides
OBJECTIVE Serum factors binding to cell nuclei were first described in the 1940s and the antibodies responsible for the binding to self (autoantibodies) discovered in the late 1950s. Routine standardized testing using a cell line (HEp-2) started in the 1980s and continues to evolve. METHODS In addition to the classic immunofluorescence assay (IFA), various immunochemical techniques have been developed
-
Progressive Pulmonary Fibrosis in Rheumatoid Arthritis-Associated Interstitial Lung Disease. J. Rheumatol. (IF 3.6) Pub Date : 2025-02-01 Jorge Rojas-Serrano
-
Pediatric Rheumatology Care in the Canadian Context: A Qualitative Analysis of Care Providers. J. Rheumatol. (IF 3.6) Pub Date : 2025-02-01 Molly J Dushnicky,Eden S Har-Gil,Jennifer J Y Lee,Deborah M Levy,
OBJECTIVE Previous work highlighted a national deficit in pediatric rheumatologists and allied health professionals with a geographic maldistribution in Canada. The aim of this current study was to further evaluate the clinical care structures and processes in place within Canadian pediatric rheumatology centres that promote or impede care delivery, from the perspective of pediatric rheumatology health
-
Urine Protein Tests in Lupus: What do They Mean? J. Rheumatol. (IF 3.6) Pub Date : 2025-02-01 Mona Aflaki,Joanne M Bargman
The development of nephritis in patients with lupus is associated with increased morbidity and mortality. Proteinuria is a key indicator of kidney involvement detecting and monitoring proteinuria is crucial as it acts as a surrogate marker for disease activity and has significant prognostic value. This review explores the general mechanisms of proteinuria and highlights the limitations of current measurement
-
Epidemiology of Antisynthetase Syndrome and Risk of Malignancy in a Population-Based Cohort (1998-2019). J. Rheumatol. (IF 3.6) Pub Date : 2025-02-01 Caitrin M Coffey,Cassondra A Hulshizer,Cynthia S Crowson,Jay H Ryu,Floranne C Ernste
OBJECTIVE Population-based epidemiology studies about antisynthetase syndrome (ASS) are lacking. Our aims were to determine the incidence and prevalence of ASS and assess malignancy risk among patients following ASS diagnosis. METHODS A retrospective, population-based cohort of adults with incident ASS residing in Olmsted County, Minnesota, in 1998-2019, was assembled. Fulfillment of Solomon classification
-
Psychometric Evaluation of the Scleroderma Skin Questionnaire: A Novel Patient-Reported Outcome for Skin Disease in Patients With Systemic Sclerosis. J. Rheumatol. (IF 3.6) Pub Date : 2025-02-01 Jeong Min Yu,John M VanBuren,Angela Child,Jessica S Alvey,Lisa A Mandl,Laura C Pinheiro,Shervin Assassi,Elana J Bernstein,Flavia V Castelino,Lorinda Chung,Luke Evnin,Tracy M Frech,Faye N Hant,Laura K Hummers,Dinesh Khanna,Kimberly S Lakin,Dorota Lebiedz-Odrobina,Yiming Luo,Ashima Makol,Jerry A Molitor,Duncan F Moore,Carrie Richardson,Nora Sandorfi,Ami A Shah,Ankoor Shah,Victoria K Shanmugam,Brian Skaug
OBJECTIVE We aimed to evaluate the psychometric properties of the Scleroderma Skin Questionnaire (SSQ), a novel patient-reported outcome (PRO) to assess systemic sclerosis (SSc)-related skin symptoms. METHODS Participants were recruited from the SSc Collaborative National Quality and Efficacy Registry (CONQUER). Internal consistency was determined using Cronbach α and McDonald ω total (ωt). The correlation
-
Baricitinib Dose Reduction in Patients With Rheumatoid Arthritis Achieving Sustained Disease Control: Final Results From the RA-BEYOND Study. J. Rheumatol. (IF 3.6) Pub Date : 2025-02-01 Christopher J Edwards,Gerhard Krönke,Jérôme Avouac,Zhanguo Li,Fabrizio Conti,Alejandro Balsa,Daojun Mo,Ewa Haladyj,Peter Fischer,Masaru Tanaka,Yasushi Takita,Kohei Hagimori,Tsutomu Takeuchi
OBJECTIVE This study examined the effect of dose step-down in patients with rheumatoid arthritis (RA) who achieved sustained disease control with baricitinib 4 mg once daily for up to 96 weeks. METHODS Patients who completed a baricitinib phase III study could enter a long-term extension (LTE). In the LTE, patients who received baricitinib 4 mg for ≥ 15 months and maintained Clinical Disease Activity
-
Potentially Avoidable Emergency Department Utilization by Persons With Psoriatic Arthritis and Ankylosing Spondylitis: A Population-Based Cohort Study. J. Rheumatol. (IF 3.6) Pub Date : 2025-02-01 Victor Mocanu,Claire E H Barber,Patrick McLane,Kelsey Chomistek,Eileen Davidson,Meghan J Elliott,Clare Hildebrandt,Steven Katz,Katie Lin,Shanon McQuitty,Nazret Russon,Brian R Holroyd,Eddy Lang,Cheryl Barnabe
OBJECTIVE Greater accessibility to ambulatory services may mitigate emergency department (ED) presentations for lower acuity issues. This study examined ED utilization patterns for individuals with psoriatic arthritis (PsA) and radiographic axial spondyloarthritis (r-axSpA) in a universal access healthcare setting. METHODS Linked population-based administrative datasets in Alberta, Canada (fiscal years
-
Effect of Characteristic Inflammatory and Structural Pelvic Magnetic Resonance Imaging Lesions on Expert Assessment of Axial Juvenile Spondyloarthritis. J. Rheumatol. (IF 3.6) Pub Date : 2025-02-01 Adam Mayer,Timothy G Brandon,Amita Aggarwal,Ruben Burgos-Vargas,Robert A Colbert,Gerd Horneff,Rik Joos,Ronald M Laxer,Kirsten Minden,Angelo Ravelli,Nicolino Ruperto,Judith A Smith,Matthew L Stoll,Shirley M Tse,Filip Van den Bosch,Walter P Maksymowych,Robert G Lambert,David M Biko,Nancy A Chauvin,Michael L Francavilla,Jacob L Jaremko,Nele Herregods,Ozgur Kasapcopur,Mehmet Yildiz,Hemalatha Srinivasalu
OBJECTIVE To evaluate the influence of pelvic magnetic resonance imaging (MRI) findings on axial disease assessment in juvenile spondyloarthritis (JSpA). METHODS This was a cross-sectional study of patients with JSpA with suspected axial disease. Three experts reviewed each case and rated their confidence (-3 to +3) in the presence of axial disease, first with clinical data and second with clinical
-
Pulmonary Arterial Hypertension Incidence in Patients With Systemic Sclerosis Treated With Bosentan for Digital Ulcers: Evidence From the SPRING-SIR Registry. J. Rheumatol. (IF 3.6) Pub Date : 2025-02-01 Fabio Cacciapaglia,Rossella De Angelis,Clodoveo Ferri,Gianluigi Bajocchi,Silvia Bellando-Randone,Cosimo Bruni,Martina Orlandi,Marco Fornaro,Edoardo Cipolletta,Giovanni Zanframundo,Roberta Foti,Giovanna Cuomo,Alarico Ariani,Edoardo Rosato,Gemma Lepri,Francesco Girelli,Elisabetta Zanatta,Silvia L Bosello,Ilaria Cavazzana,Francesca Ingegnoli,Maria De Santis,Giuseppe Murdaca,Giuseppina Abignano,Pettiti
OBJECTIVE Bosentan (BOS) is approved for treating pulmonary arterial hypertension (PAH) and preventing digital ulcers (DU) in systemic sclerosis (SSc). Our study aimed to evaluate whether BOS prescribed for DU could reduce the incidence of PAH in a large SSc cohort from the Systemic Sclerosis Progression Investigation (SPRING) registry. METHODS Patients with SSc from the SPRING registry, meeting 2013
-
Performance of Disease Activity Indices Used in Axial Spondyloarthritis in Real-World Clinical Settings. J. Rheumatol. (IF 3.6) Pub Date : 2025-02-01 Sara Alonso,Ignacio Braña,Marta Loredo,Estefanía Pardo,Stefanie Burger,Rubén Queiro
OBJECTIVE Monitoring axial spondyloarthritis (axSpA) disease activity using validated indices (eg, Bath Ankylosing Spondylitis Disease Activity Index [BASDAI], Axial Spondyloarthritis Disease Activity Score [ASDAS]) is widely recommended but rarely followed in practice. The reasons, although varied, may be found in the scarcity of studies comparing the performance of these indices in daily practice
-
Mortality in Patients With Sjögren Disease: A Prospective Cohort Study Identifying Key Predictors. J. Rheumatol. (IF 3.6) Pub Date : 2025-02-01 Olga Rusinovich Lovgach,Zulema Plaza,Mónica Fernández Castro,José Rosas,Victor Martínez-Taboada,Alejandro Olivé,Raul Menor Almagro,Belen Serrano Benavente,Judit Font-Urgelles,Angel Garcia-Aparicio,Sara Manrique-Arija,Alberto Garcia-Vadillo,Ruth Lopez-Gonzalez,Javier Narvaez García,María Beatriz Rodriguez-Lozano,Carlos Galisteo,Juan Jorge Gonzalez-Martin,Paloma Vela-Casasempere,Cristina Bohorquez,Celia
OBJECTIVE We aimed to quantify the mortality risk in a large, well-characterized cohort of patients with Sjögren disease (SjD) and to identify independent predictors of mortality in this population. METHODS We included 314 patients diagnosed with SjD according to the 2002 American-European Consensus Group criteria from a prospective, multicenter SjögrenSER Prospective cohort. Detailed data on systemic
-
Incidence and Risk of Infections in Patients With Radiographic Axial Spondyloarthritis Receiving Biologic Therapies: A Prospective Observational Study Using the KOBIO Registry. J. Rheumatol. (IF 3.6) Pub Date : 2025-02-01 Kyung Min Ko,Su-Jin Moon
OBJECTIVE This study aimed to assess the occurrence of infection and risk factors among patients with radiographic axial spondyloarthritis (r-axSpA) treated with biologics in a real-world setting. METHODS This prospective observational cohort study included patients with r-axSpA from the Korean College of Rheumatology Biologics (KOBIO) registry who initiated or switched to a biologic agent between
-
Systemic Granulomatosis With Polyangiitis Presenting With Bilateral Renal Masses. J. Rheumatol. (IF 3.6) Pub Date : 2025-01-15 Nehaal Ahmed,Saad Rashid,Kenneth J Warrington,Matthew J Koster
-
Skin Eruption and Nerve Impairment: Eosinophil Activation Link. J. Rheumatol. (IF 3.6) Pub Date : 2025-01-15 Kazuro Kamada,Yuichiro Fujieda,Mika Watanabe,Tatsuya Atsumi
-
Clinical expression of radiographic axial spondyloarthritis and its association with HLA-B27 in European and Ibero-American populations. J. Rheumatol. (IF 3.6) Pub Date : 2025-01-15 María Ángeles Puche-Larrubia,Lourdes Ladehesa-Pineda,Pilar Font-Ugalde,Rubén Burgos-Vargas,Percival Sampaio-Barros,José Maldonado-Cocco,Anabela Barcelos,Jordi Gratacós,Xavier Juanola,Alejandro Escudero-Contreras,Janitzia Vázquez-Mellado,Iván Arias de la Rosa,Eduardo Collantes-Estévez,Clementina López-Medina
OBJECTIVE To compare the clinical and sociodemographic characteristics of Ibero-American patients with radiographic axial spondyloarthritis (r-axSpA) to those of European patients, with a particular focus on the influence of HLA-B27. METHODS This was an observational, cross-sectional, and multicentre study of patients who fulfilled the European Spondyloarthropathy Study Group (ESSG) criteria for SpA
-
Association between patient perception of disease status and different components of the Minimal Disease Activity (MDA) criteria in psoriatic arthritis. J. Rheumatol. (IF 3.6) Pub Date : 2025-01-15 Sarah M Yazji,Philip S Helliwell,Andra Balanescu,Emmanuelle Dernis,Uta Kiltz,Umut Kalyoncu,Ying Ying Leung,Ana-Maria Orbai,Josef S Smolen,Maarten de Wit,Laure Gossec,Laura C Coates
OBJECTIVE The aim of this analysis was to evaluate the relationship between the criteria met of the Minimal Disease Activity (MDA) score for psoriatic arthritis (PsA) and patient-perceived disease status. METHODS We analysed data from the ReFlaP study (NCT03119805), a cross-sectional international study of adult patients with PsA. Patients self-reported if they felt their PsA was in remission (REM)
-
Serum Biomarkers of Pulmonary Damage and Risk for Progression of Rheumatoid Arthritis-Associated Interstitial Lung Disease. J. Rheumatol. (IF 3.6) Pub Date : 2025-01-15 Sung Hae Chang,Yong-Beom Park,Gregory C McDermott,Misti L Paudel,Keigo Hayashi,You-Jung Ha,Jeong Seok Lee,Min Uk Kim,Chan Ho Park,Ji-Won Kim,Jang Woo Ha,Sang Wan Chung,Sung Won Lee,Eun Ha Kang,Yeon Ah Lee,Jung-Yoon Choe,Eun Young Lee,Jeffrey A Sparks
OBJECTIVE To investigate baseline and change of pulmonary damage biomarkers (serum Krebs von den Lungen 6 [KL-6], human surfactant protein D [hSP-D], and matrix metalloproteinase 7 [MMP-7]) with rheumatoid arthritis-associated interstitial lung disease (RA-ILD) progression. METHODS In the Korean Rheumatoid Arthritis Interstitial Lung Disease (KORAIL) cohort, a prospective cohort, we enrolled patients
-
Uncommon Clinical and Radiological Presentation of Monosodium Urate Crystal Deposition in Parotid Glands. J. Rheumatol. (IF 3.6) Pub Date : 2025-01-15 Kei Yiu Douglas Hui,Huiliang Koh,Andrew Makmur,Ju Ee Seet
-
The Reshaping of Modifiable Risk Factors as a Strategy to Prevent the Development of Rheumatoid Arthritis. J. Rheumatol. (IF 3.6) Pub Date : 2025-01-15 Francesco Caso,Roberto Giacomelli,Marcella Nunziato,Federica Di Maggio,Raffaele Scarpa,Piero Ruscitti,Francesco Salvatore
-
Clinical characteristics and influencing factors of hyperkyphosis in a Chinese Cohort with axial spondyloarthritis: a multicentre retrospective study. J. Rheumatol. (IF 3.6) Pub Date : 2025-01-15 Yuening Chen,Zhaoyang Geng,Yu Wang,Hongxiao Liu
OBJECTIVE This study aimed to investigate the clinical characteristics and influencing factors of axial spondyloarthritis (axSpA) hyperkyphosis in a Chinese cohort. METHODS A cross-sectional study was conducted on 607 patients with axSpA attending 12 hospitals across 11 centers from March 2022 to March 2024.Univariate and multivariate logistic regression analyses were used to explore the relevant influencing
-
Association between abatacept exposure levels and infection occurrence in patients with rheumatoid arthritis: post hoc analysis of the AVERT-2 study. J. Rheumatol. (IF 3.6) Pub Date : 2025-01-15 Paul Emery,Roy Fleischmann,Robert Wong,Karissa Lozenski,Yoshiya Tanaka,Vivian P Bykerk,Clifton O Bingham,Thomas W J Huizinga,Gustavo Citera,Vidya Perera,Bindu Murthy,Kelly Fellows Maxwell,Julie Passarell,William D Hedrich,Daphne Williams
OBJECTIVE To determine if higher serum exposure during subcutaneous (SC) abatacept treatment was associated with an increased infection risk in adult patients with early rheumatoid arthritis (RA). METHODS Data from AVERT-2 (Assessing Very Early Rheumatoid arthritis Treatment-2, NCT02504268), a randomized, placebo-controlled study in anticitrullinated protein antibody- positive patients with early RA
-
Inpatient management of gout: we are still failing. J. Rheumatol. (IF 3.6) Pub Date : 2025-01-15 Kate Alfeld,Murray L Barclay,Richard McNeill,Chris Frampton,Matt Doogue,Lisa K Stamp
OBJECTIVE Despite effective treatment, gout is poorly managed. The aim of this study was to determine rates of serum urate (SU) testing and allopurinol dose adjustment in patients on allopurinol admitted to Christchurch based hospitals. METHODS The hospital electronic prescribing and administration (ePA) system was used to identify patients on allopurinol during hospital admissions from March 2016-March
-
Mind Matters in Rheumatoid Arthritis: The Rising Burden of Anxiety and Depression. J. Rheumatol. (IF 3.6) Pub Date : 2025-01-15 Nadia Sweet,Heather Huang,Christie M Bartels
-
Rheumatoid Arthritis Treatment Has Changed Dramatically Over the Past 3 Decades, but Has the Disease Itself Changed? J. Rheumatol. (IF 3.6) Pub Date : 2025-02-01 Carol A Hitchon,Hani S El-Gabalawy
-
Knowledge About Human Papillomavirus Among Patients With Immune-Mediated Inflammatory Diseases. J. Rheumatol. (IF 3.6) Pub Date : 2025-02-01 Tiphaine Goulenok,Arthur Mageau,Chrystelle François,Claire Dossier,Eric Hachulla,Thomas Papo,Karim Sacré
-
What's in a Name: The Value of Defining Core Competencies for Extended Role Practitioners in Arthritis Care. J. Rheumatol. (IF 3.6) Pub Date : 2025-02-01 Amanda Steiman,Katie Lundon,Laura Passalent,Leslie Soever,Deborah M Levy,Christopher Nielsen,Rachel Shupak
-
Use of Single-Arm Observational Data for Causal Inference: The Case of GLA:D for Hip and Knee Osteoarthritis. J. Rheumatol. (IF 3.6) Pub Date : 2025-02-01 Daniel L Riddle,Ian A Harris,Robin Christensen
-
Effect of Age on Rheumatic Immune-Related Adverse Events: Experience From the Canadian Research Group of Rheumatology in Immuno-Oncology (CanRIO). J. Rheumatol. (IF 3.6) Pub Date : 2025-02-01 Jenny Xiaoyu Li,Marie Hudson,Carrie Ye,Janet Roberts,Aurore Fifi-Mah,May Y Choi,Sabrina Hoa,C Thomas Appleton,Janet Pope,Nancy Maltez,Lourdes Gonzalez Arreola,Anthony Obrzut,Shahin Jamal,
OBJECTIVE Immune checkpoint inhibitors (ICIs) have revolutionized cancer outcomes but are limited by immune-related adverse events (irAEs), including rheumatic irAEs (Rh-irAEs). Aging is associated with increased inflammation, referred to as "inflammaging." In this study, we explore the effect of age on severity, frequency, and treatment of Rh-irAEs. METHODS Adults with new Rh-irAEs after ICI exposure
-
Nintedanib in Rheumatoid Arthritis-Related Interstitial Lung Disease: Real-World Safety Profile and Risk of Side Effects and Discontinuation. J. Rheumatol. (IF 3.6) Pub Date : 2025-01-15 Marco Sebastiani,Gemma Lepri,Claudia Iannone,Emanuele Bozzalla Cassione,Giuliana Guggino,Andrea Lo Monaco,Roberta Foti,Marco Fornaro,Maria Sole Chimenti,Angelo Fassio,Simona Truglia,Francesca Cozzini,Antonio Carletto,Alessandro Giollo,Addolorata Corrado,Chiara Bazzani,Serena Guiducci,Ennio Favalli,Serena Bugatti,Florenzo Iannone,Roberto Caporali,Andreina Manfredi
OBJECTIVE Some concerns remain about the safety of nintedanib in patients with rheumatoid arthritis-related interstitial lung disease (RA-ILD), such as in the presence of comorbidities or in combination with biologic, targeted synthetic, and/or conventional synthetic disease-modifying antirheumatic drugs (DMARDs). In this multicenter study, we retrospectively evaluated the safety of nintedanib in a
-
Cancer Incidence and Outcome for Patients With Rheumatoid Arthritis: A Long-Term Population Study in Western Australia. J. Rheumatol. (IF 3.6) Pub Date : 2025-01-15 Johannes Nossent,Helen I Keen,David B Preen,Charles A Inderjeeth
OBJECTIVE Our aim was to compare the incidence of malignancy and its effect on mortality between hospitalized patients with rheumatoid arthritis (RA) and controls. METHODS We conducted a population-level observational study of patients with RA (International Classification of Diseases, 9th revision, Clinical Modification [ICD-9-CM] code 714 and International Statistical Classification of Diseases and
-
IgG4-Related Arterial Disease: An Unusual Case of Aortitis. J. Rheumatol. (IF 3.6) Pub Date : 2024-12-15 Martin Soubrier,Eric Hachulla
-
Effective Use of Apremilast in Refractory Arthritis Associated With Cystic Fibrosis. J. Rheumatol. (IF 3.6) Pub Date : 2024-12-15 Angelo Nigro
-
High-Sensitivity Cardiac Troponin T as a Marker to Improve Cardiovascular Disease Risk Assessment Among Patients With Rheumatoid Arthritis. J. Rheumatol. (IF 3.6) Pub Date : 2024-12-15 Gang Wang,Zhichun Liu
-
-
Managing Giant Cell Arteritis With Tocilizumab: Relapses and Adverse Events. J. Rheumatol. (IF 3.6) Pub Date : 2024-12-15 Miguel Ángel González-Gay,Santos Castañeda,Iván Ferraz-Amaro
-
The Early Course of Radiographic Progression in Axial Spondyloarthritis: Have We Missed Something? J. Rheumatol. (IF 3.6) Pub Date : 2025-02-01 Jürgen Braun
-
Effects of Biologics on Temporomandibular Joint Inflammation in Juvenile Idiopathic Arthritis. J. Rheumatol. (IF 3.6) Pub Date : 2025-02-01 Peter Stoustrup,Christian J Kellenberger,Christian Høst,Annelise Küseler,Thomas K Pedersen,Troels Herlin,Mia Glerup
OBJECTIVE This prospective study investigates the efficacy of biologics in combination with methotrexate (MTX) or leflunomide (LEF) on juvenile idiopathic arthritis (JIA)-related temporomandibular joint (TMJ) arthritis measured by magnetic resonance imaging (MRI)-based inflammation score and deformity score. METHODS A prospective, single-center observational cohort study of 18 consecutive patients
-
Association of the Apollo Wearable With Fatigue, Raynaud Phenomenon, and Quality of Life in Patients With Systemic Sclerosis: A Pilot Study. J. Rheumatol. (IF 3.6) Pub Date : 2025-02-01 Krista Hammaker,Haomin Hu,Maureen Laffoon,Leigh A Freno,Robert Lafyatis,Yongseok Park,Robyn T Domsic
OBJECTIVE In patients with systemic sclerosis (SSc), fatigue is the highest-ranked symptom affecting quality of life (QOL), followed by Raynaud phenomenon (RP). We report results from a pilot study of the Apollo wearable device in patients with SSc. METHODS Twenty-five adult participants with SSc, moderate fatigue, and RP were enrolled. Participants completed a 4-week intervention, during which they
-
Exome Sequencing of Chinese Patients With Anticitrullinated Protein Antibody-Positive Rheumatoid Arthritis in Singapore. J. Rheumatol. (IF 3.6) Pub Date : 2025-01-15 Khai Pang Leong,Mei Yun Yong,Ee Tzun Koh,Peter Pak Moon Cheung,Manjari Lahiri,Chin Teck Ng,Chia Mun Woo,Liuh Ling Goh,Sandy Hong Hong Lim,Preeti Dhanasekaran,Grace Yee May Cheah,Justina Wei Lyn Tan,Wenchao Hu,Mei Ling Chong,Vikrant Kumar,Sonia Davila,
OBJECTIVE More than 130 susceptibility loci for rheumatoid arthritis (RA) have been identified with genome-wide association studies. To investigate the genetic predisposition of Chinese patients to anticitrullinated protein antibody (ACPA)-positive RA, we carried out an exome sequencing study. METHODS Patients were recruited from 3 major public hospitals in Singapore: Tan Tock Seng Hospital (TTSH)
-
Epidemiology of Isolated Cutaneous Lupus Erythematosus in the Multiethnic Population of Reunion Island: A Retrospective Multicenter Study. J. Rheumatol. (IF 3.6) Pub Date : 2025-01-15 Mathurin Maillet,Babacar S Tounkara,Damien Vagner,Kelly Bagny,Sébastien Duquenne,Céline Lartigau-Roussin,Anne Kolbe,Yves Lauret,Andry Randrianjohany,Serge Laureau,Nicole Denat,Aude Alquier,Nathalie Sultan-Bichat,Antoine Bertolotti,Loïc Raffray
OBJECTIVE Few data are available about the epidemiology of cutaneous lupus erythematosus (CLE) in the Southern hemisphere and in multiethnic populations. We describe the prevalence, incidence, and clinical characteristics of isolated CLE in the multiethnic population of Reunion Island, France, including patients with dark skin. METHODS The study was performed in all public hospitals and private dermatology
-
Improving Gout Care in a Canadian Academic Medical Center Through a Multidisciplinary Nurse-Led Protocol. J. Rheumatol. (IF 3.6) Pub Date : 2024-12-15 Thomas Audet,Marie-Aude Picard-Turcot,Julie Robindaine,Nathalie Carrier,Pierre Dagenais
OBJECTIVE Following Health Canada's knowledge translation framework, we report the results of a clinical audit from 2012 to 2015 followed by a multidisciplinary, nurse-led gout care protocol with a treat-to-target (T2T) strategy implemented in April 2018. METHODS A clinical audit with chart reviewing was completed for adults with gout and urate-lowering therapy (ULT) indication at the Centre Hospitalier
-
Update on Tacrolimus in Patients With Interstitial Pneumonia Associated With Polymyositis or Dermatomyositis: 3-Year Postmarketing Surveillance Follow-Up in Japan. J. Rheumatol. (IF 3.6) Pub Date : 2024-12-01 Masataka Kuwana,Naoko Wakasugi,Tetsuji Hashida,Satoshi Uno,Takafumi Suda
-
Evaluating and Refining Strategies for Rheumatoid Arthritis Prevention in First Nations Communities. J. Rheumatol. (IF 3.6) Pub Date : 2024-12-01 Sijia Liu,Ruwei Hu
-
Pursuing Gender Equity in Rheumatology: Thinking Beyond Gender Representation to Assess Gender Equality. J. Rheumatol. (IF 3.6) Pub Date : 2025-02-01 Laura Ross,Stephanie Bond,Jessica A Day
-
Association of Past Smoking Status With Gout in Māori People in Aotearoa New Zealand. J. Rheumatol. (IF 3.6) Pub Date : 2025-02-01 Niamh C Fanning,John F Pearson,Nicola Dalbeth,Huti Watson,Tony R Merriman,Lisa K Stamp
OBJECTIVE Evidence for an association of smoking with gout is conflicting. We assessed associations of current and past smoking with gout in an Aotearoa New Zealand (NZ) population. METHODS Multivariable logistic regression analysis was performed on cross-sectional data from participants of NZ Māori (from 2 studies: Genetics of Gout in Aotearoa [GGA] study of 293 participants with gout and 431 without;
-
Patient Profiles in Randomized Controlled Trials Versus a Real-World Study in Psoriatic Arthritis: Scoping Review and Metaanalysis. J. Rheumatol. (IF 3.6) Pub Date : 2025-02-01 Gelsomina Alle,Clementina Lopez-Medina,Stefan Siebert,Frédéric Lavie,Wim Noel,Josef S Smolen,Laure Gossec
OBJECTIVE Patients with psoriatic arthritis (PsA) in randomized controlled trials (RCTs) may not reflect patients with PsA in clinical practice. Our objective was to perform a metaanalysis comparing the characteristics of patients with PsA in RCTs of biologic disease-modifying antirheumatic drugs (bDMARDs) to patient profiles in a real-world study. METHODS Data sources included (1) a scoping literature
-
Large Language Models in Rheumatologic Diagnosis: A Multimodal Performance Analysis. J. Rheumatol. (IF 3.6) Pub Date : 2025-02-01 Mahmud Omar,Reem Agbareia,Eyal Klang,Mohammaed E Naffaa
-
Evaluation of Myocarditis in Patients With Still Disease: Clinical Findings From the Multicenter International AIDA Network Still Disease Registry. J. Rheumatol. (IF 3.6) Pub Date : 2025-01-15 Piero Ruscitti,Ilenia Di Cola,Antonio Vitale,Valeria Caggiano,Pierpaolo Palumbo,Ernesto Di Cesare,Jiram Torres-Ruiz,Guillermo Arturo Guaracha-Basañez,Eduardo Martín-Nares,Francesco Ciccia,Daniela Iacono,Flavia Riccio,Maria Cristina Maggio,Samar Tharwat,Soad Hashad,Donato Rigante,Augusta Ortolan,Henrique A Mayrink Giardini,Isabele Parente de Brito Antonelli,Rafael Alves Cordeiro,Roberto Giacomelli,Luca
OBJECTIVE We aimed to (1) evaluate the cardiac involvement, with a focus on myocarditis, in patients with Still disease included in the multicenter Autoinflammatory Disease Alliance (AIDA) Network Still disease registry; and (2) assess the predictive factors for myocarditis by deriving a clinical risk patient profile for this severe manifestation. METHODS A multicenter observational study was established
-
Broadening the Landscape for Treatment Recommendations in the Management of Axial Spondyloarthritis. J. Rheumatol. (IF 3.6) Pub Date : 2025-01-01 Wilson Bautista-Molano
-
Cardiovascular Health and Adverse Pregnancy Outcomes in Autoimmune Rheumatic Diseases. J. Rheumatol. (IF 3.6) Pub Date : 2025-01-01 Vijaya Prasanna Parimi,Vinod Ravindran